Psychedelic-Assisted Therapy: What Emerging Research Shows

Psychedelic-assisted therapy is among the most discussed developments in mental health research, drawing extraordinary scientific, media, and popular interest as clinical trials have produced promising results for conditions including treatment-resistant depression, PTSD, addiction, and end-of-life anxiety. The research renaissance follows decades during which Schedule I classification effectively halted clinical investigation, and early results are generating significant optimism, though the field is still early and significant questions remain about mechanisms, protocols, populations, and the path from research to practice. Psilocybin, the active compound in psychedelic mushrooms, has been the most extensively studied compound in the current research wave. Phase 2 clinical trials at Johns Hopkins, Imperial College London, and NYU have found large and lasting antidepressant effects in patients with major depressive disorder and treatment-resistant depression. The COMPASS Pathways phase 2b trial, the largest clinical trial of psilocybin to date, found significant antidepressant effects for the 25-milligram dose compared to a 1-milligram control dose at three weeks. Phase 3 trials are ongoing and necessary before regulatory approval can be pursued. The mechanism through which psychedelics produce therapeutic effects is an active area of research. Proposed mechanisms include neuroplasticity effects, with psychedelics inducing a period of increased synaptic plasticity that may allow therapeutic changes to occur more readily; alterations in default mode network activity, the resting-state brain network associated with self-referential thought and rumination; mystical or transformative experiences, which correlate with therapeutic outcomes in multiple studies; and changes in psychological flexibility, creativity, and openness. The mystical experience hypothesis is particularly intriguing and controversial, as it suggests that subjective experience, not just pharmacological effects, mediates outcomes. MDMA-assisted therapy for PTSD has been studied extensively by the Multidisciplinary Association for Psychedelic Studies. Phase 3 clinical trials showed large effects on PTSD symptoms compared to placebo-assisted therapy. The FDA reviewed the application for approval in 2024 but requested additional data, declining to approve the application based on concerns including study design issues, potential unblinding from the drug's perceptible effects, and concerns about adverse events in specific populations. The development continues with MAPS working to address FDA concerns. Ketamine is the only psychedelic-adjacent compound with current regulatory approval for depression. Esketamine nasal spray received FDA approval in 2019 for treatment-resistant depression and has been adopted in clinical practice. Ketamine infusions delivered intravenously are used off-label for treatment-resistant depression. Research documents rapid antidepressant effects, often within hours, that are distinctive in a field where standard antidepressants require weeks to show effects. The durability of ketamine's effects without maintenance treatment is more limited, and the optimal protocols for maintenance treatment are still being developed. The therapeutic context, including the therapist relationship and the setting in which sessions occur, is understood to be integral to outcomes in psychedelic-assisted therapy, distinguishing it from standard pharmacotherapy. Psychedelic therapy protocols typically involve multiple preparation sessions, one or more medicine sessions in which the therapist is present throughout, and integration sessions afterward. The therapist's role in this process is different from standard psychotherapy and requires specialized training that the field is still developing. Risks and safety are areas requiring careful attention as enthusiasm for the field grows. Psychedelics can produce acute distress, psychosis-like states, and lasting adverse psychological effects in some individuals, particularly those with personal or family histories of psychotic disorders. Screening protocols in clinical research have excluded these higher-risk populations, but real-world implementation will need to navigate screening carefully. The therapeutic container, the relationship, setting, and protocol, substantially affects the quality of the psychedelic experience and the risk of adverse outcomes. The regulatory pathway for psychedelic therapies involves both compound approval and therapy protocol approval, which is more complex than standard drug approval. Questions about how psychedelic therapy training should be regulated, how therapists who conduct sessions should be supervised, and how the compounds should be controlled while remaining accessible to patients are being worked out as the field develops. The cultural and social dimensions of the psychedelic renaissance deserve acknowledgment. Indigenous communities have used psychedelic plants in ceremonial and healing contexts for centuries, and the current research wave has generated questions about intellectual property, cultural appropriation, and equitable benefit sharing. The commercialization of psychedelic therapy also raises questions about who will be able to access it: current treatment protocols are expensive and not yet covered by insurance, which could make psychedelic therapy accessible only to wealthy individuals in the near term.